Prognostic biomarkers in lung cancer patients in terms of long-term survival
Introduction: We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy. Methods: Fourty eight patients with advanced stage lung cancer were included in the study. Dem...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nizameddin KOCA
2021-03-01
|
| Series: | Turkish Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/1559578 |
| _version_ | 1797909707284807680 |
|---|---|
| author | Belkis Nihan Coskun Engin Ulukaya Türkkan Evrensel Şeniz Korkmaz Oğuzhan Sıtkı Dizdar |
| author_facet | Belkis Nihan Coskun Engin Ulukaya Türkkan Evrensel Şeniz Korkmaz Oğuzhan Sıtkı Dizdar |
| author_sort | Belkis Nihan Coskun |
| collection | DOAJ |
| description | Introduction:
We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy.
Methods:
Fourty eight patients with advanced stage lung cancer were included in the study. Demographic data and histopathological characteristics of the patients were recorded. Serum levels of M30 and M65 were studied in 48 patients before chemotherapy, and in 43 patients both before and 48 hours after chemotherapy. Long-term survival was evaluated using Kaplan-Meier curves. The effect of high or low M30, M65 levels and M30/M65 ratio on long-term survival was investigated.
Results: The mean age of the patients at the time of diagnosis was 57.52 ± 9.38 years. Fourty six of the 48 patients were men. While M30 value before chemotherapy was 163.23 ± 112.30 U/l; It was measured as 249.74 ± 266.67 U/l 48 hours after chemotherapy (p |
| first_indexed | 2024-04-10T11:13:09Z |
| format | Article |
| id | doaj.art-b1770dbca39b41b5b6f237694c2704b4 |
| institution | Directory Open Access Journal |
| issn | 2687-4245 |
| language | English |
| last_indexed | 2024-04-10T11:13:09Z |
| publishDate | 2021-03-01 |
| publisher | Nizameddin KOCA |
| record_format | Article |
| series | Turkish Journal of Internal Medicine |
| spelling | doaj.art-b1770dbca39b41b5b6f237694c2704b42023-02-15T16:18:58ZengNizameddin KOCATurkish Journal of Internal Medicine2687-42452021-03-013Supplement 1202210.46310/tjim.8754371881Prognostic biomarkers in lung cancer patients in terms of long-term survivalBelkis Nihan Coskun0Engin Ulukaya1Türkkan Evrensel2Şeniz Korkmaz3Oğuzhan Sıtkı Dizdar4TIP FAKÜLTESİISTINYE UNIVERSITYULUDAG UNIVERSITYKaracabey Devlet HastanesiDepartment of Internal Medicine and Clinical Nutrition, Kayseri City Training and Research HospitalIntroduction: We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy. Methods: Fourty eight patients with advanced stage lung cancer were included in the study. Demographic data and histopathological characteristics of the patients were recorded. Serum levels of M30 and M65 were studied in 48 patients before chemotherapy, and in 43 patients both before and 48 hours after chemotherapy. Long-term survival was evaluated using Kaplan-Meier curves. The effect of high or low M30, M65 levels and M30/M65 ratio on long-term survival was investigated. Results: The mean age of the patients at the time of diagnosis was 57.52 ± 9.38 years. Fourty six of the 48 patients were men. While M30 value before chemotherapy was 163.23 ± 112.30 U/l; It was measured as 249.74 ± 266.67 U/l 48 hours after chemotherapy (phttps://dergipark.org.tr/tr/download/article-file/1559578lung cancerm30 and m65 antigenneoadjuvant therapylong-term prognosis |
| spellingShingle | Belkis Nihan Coskun Engin Ulukaya Türkkan Evrensel Şeniz Korkmaz Oğuzhan Sıtkı Dizdar Prognostic biomarkers in lung cancer patients in terms of long-term survival Turkish Journal of Internal Medicine lung cancer m30 and m65 antigen neoadjuvant therapy long-term prognosis |
| title | Prognostic biomarkers in lung cancer patients in terms of long-term survival |
| title_full | Prognostic biomarkers in lung cancer patients in terms of long-term survival |
| title_fullStr | Prognostic biomarkers in lung cancer patients in terms of long-term survival |
| title_full_unstemmed | Prognostic biomarkers in lung cancer patients in terms of long-term survival |
| title_short | Prognostic biomarkers in lung cancer patients in terms of long-term survival |
| title_sort | prognostic biomarkers in lung cancer patients in terms of long term survival |
| topic | lung cancer m30 and m65 antigen neoadjuvant therapy long-term prognosis |
| url | https://dergipark.org.tr/tr/download/article-file/1559578 |
| work_keys_str_mv | AT belkisnihancoskun prognosticbiomarkersinlungcancerpatientsintermsoflongtermsurvival AT enginulukaya prognosticbiomarkersinlungcancerpatientsintermsoflongtermsurvival AT turkkanevrensel prognosticbiomarkersinlungcancerpatientsintermsoflongtermsurvival AT senizkorkmaz prognosticbiomarkersinlungcancerpatientsintermsoflongtermsurvival AT oguzhansıtkıdizdar prognosticbiomarkersinlungcancerpatientsintermsoflongtermsurvival |